首页 > 市场调查报告书 > 製药

分子标靶治疗学

市场调查报告书

商品编码

1951550

全球铁凋亡标靶治疗市场：市场机会、治疗方法、技术开发平台和临床试验展望（2026年）

Global Ferroptosis Targeting Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026

出版日期: 2026年02月01日 | 出版商:

KuicK Research | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球铁凋亡标靶治疗市场 - 市场机会、治疗方法、技术开发平台和临床试验展望（2026年）研究结果和亮点：

全球与区域市场机会分析
临床试验中领先疗法的见解：超过 15 种疗法
铁凋亡标靶治疗临床试验趋势（依公司、国家、适应症和阶段划分）
铁凋亡标靶治疗临床趋势与特定适应症创新展望
关键临床试验启动与完成年份
FDA 和 EMA 认定洞察：孤儿药、快速通道
铁凋亡治疗开发的技术平台与方法

需求铁凋亡标靶治疗及本报告的意义

铁凋亡标靶治疗已成为治疗多种疾病（包括癌症、神经退化性疾病和缺血性损伤）的新方法。铁凋亡是一种受控细胞死亡，由铁依赖性和脂质过氧化驱动的机制介导，能够选择性地清除病变细胞，提供了一种不同于化疗和免疫疗法的治疗途径。这项特性使其对胶质母细胞瘤和三阴性乳癌等抗药性癌症特别有效，因为传统疗法通常对这些癌症无效。

由于现有疗法的局限性，人们需要基于铁凋亡的疗法。化疗和免疫疗法虽然有效，但随着时间的推移容易产生抗药性，并且通常伴随全身毒性。因此，铁凋亡靶向癌细胞特有的代谢通路，为更精确地诱导细胞死亡并最大限度地减少对正常组织的附带损伤提供了一种很有前景的方法。

本报告目的是帮助製药公司、投资者、研究机构和其他利害关係人了解铁凋亡的当前治疗格局。报告基于进行中的临床试验、技术平台和主要参与者，重点阐述了铁凋亡作为重要治疗标靶的巨大潜力。

本报告包含的临床研究和试验见解

本报告全面分析了针对铁凋亡的临床研究和试验，涵盖各个治疗领域，特别是在肿瘤领域，包括单药治疗和联合治疗。特别值得注意的是，多项研究探索铁凋亡诱导剂与传统疗法（如化疗、免疫疗法和标靶疗法）的联合作用。这些联合疗法目的是克服肿瘤抗药性并提高治疗反应，确保患者获得更好的治疗效果。

本报告也涵盖了其他治疗领域的临床试验，包括阿兹海默症和帕金森氏症等神经退化性疾病。在这些疾病中，铁凋亡与氧化压力导致的细胞死亡过程密切相关。早期临床前资料表明，铁凋亡抑制剂可能具有神经保护作用，能够预防神经元损伤并保护脑功能。本报告也深入分析了临床试验申办方，包括大型製药公司、生技公司和学术机构。这有助于利害关係人识别推动创新的关键参与者，并评估区域趋势，尤其是在中国等新兴市场，儘管存在监管障碍，但铁凋亡疗法的应用加速发展。

从事铁凋亡标靶疗法研发的主要公司

包括PTC Therapeutics、BeBetter Med和住友製药在内的行业主要参与者正致力于开发铁凋亡标靶疗法。这些公司开发用于治疗癌症和神经退化性疾病等疾病的铁凋亡诱导剂和抑制剂。例如，PTC Therapeutics 目前专注于实验性药物 "vatiquinone" ，该药物靶向氧化压力通路，并在癌症和Friedreich氏失调症的临床试验中显示出积极结果。

本报告揭示了这些公司的研发策略和产品线，使利害关係人能够更清晰地了解该领域的未来发展。基于后期临床试验的进展，基于铁凋亡的疗法很可能即将实现商业化。此外，与新兴生物技术公司和学术机构的合作产生创新方法，例如奈米载体系统和双效分子，这些方法有可能进一步提高铁凋亡疗法的疗效和特异性。

报告：确定铁凋亡标靶疗法的未来发展方向

本报告预测，铁凋亡标靶疗法将继续快速发展，尤其是在个人化医疗领域。对生物标记的深入研究有望更准确地预测患者的治疗反应，并实现更个人化、更有效且副作用更少的治疗。将铁凋亡诱导剂与免疫疗法、放射疗法和标靶疗法结合，以提高癌症治疗效果，也成为一种趋势。此外，奈米颗粒等药物递送系统的进步有望提高这些疗法的靶向性和生物利用度。

随着临床试验的不断进行和投资的增加，基于铁凋亡的疗法前景光明。这些疗法甚至可能彻底改变癌症和其他细胞死亡相关疾病的治疗方式。

Global & Regional Market Opportunity Analysis
Clinical Trials Insight On Key Therapies In Trials: > 15 Therapies
Ferroptosis Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
Ferroptosis Targeting Therapies Clinical Trends & Innovations Outlook By Indications
Key Clinical Studies Initiation & Completion Year Overview
FDA & EMA Designations Insight: Orphan, Fast Track
Technological Platforms & Approaches For Ferroptosis Therapeutic Development

Ferroptosis Targeted Therapies Need & Why This Report?

Ferroptosis targeted therapies have emerged as a novel approach to the treatment of several diseases, including cancer, neurodegenerative disorders and ischemic injuries. Ferroptosis is a type of regulated cell death that is driven by iron dependent and lipid peroxidation driven mechanisms, providing a different approach to the selective elimination of diseased cells than chemotherapy or immunotherapy. This makes it an especially useful approach for drug resistant cancers, such as glioblastoma and triple negative breast cancer, for which conventional treatment modalities commonly fail.

The need for ferroptosis based therapies emanates from the shortcomings of the current treatment modalities. Chemotherapy and immunotherapy, though effective, usually result in resistance over time, with their attendant systemic toxicity. Ferroptosis, therefore, with its targeted action on metabolic pathways unique to cancer cells, promises a more precise way to induce cell death with reduced collateral damage to normal tissues.

This report is designed to help stakeholders understand the current therapeutic landscape of ferroptosis, including pharmaceutical companies, investors, and research institutions. Based on ongoing clinical trials, technological platforms, and key players, the report has indicated the expanding potential of ferroptosis as a vital target for therapeutic development.

Clinical Studies & Trials Insight Included In Report

This report comprehensively analyzes ongoing clinical studies and trials targeting ferroptosis across therapeutic areas. This includes both monotherapies and combination therapies, particularly in cancer treatment. Most notably, several studies are considering the efficacy of combining the administration of ferroptosis inducers with more traditional therapies, such as chemotherapy, immunotherapy, and targeted treatments. These combinations have been developed to circumvent tumor resistance, improve therapeutic response, and thus ensure better outcomes for patients.

The report also encompasses clinical trials in other therapeutic areas, including neurodegenerative diseases like Alzheimer's and Parkinson's, where ferroptosis has been implicated in the cell death process due to oxidative stress. Early preclinical data suggests that inhibitors of ferroptosis may have neuroprotective effects, which can prevent neuronal damage and maintain brain function. Furthermore, the report provides insight into trial sponsors, including major pharmaceutical companies, biotech firms, and academic institutions. This helps stakeholders to identify the key players driving innovation and to assess the geographical landscape, especially emerging markets such as China, where adoption of ferroptosis therapies is accelerating even against a backdrop of regulatory hurdles.

Leading Companies Engaged In R&D Of Ferroptosis Targeted Therapies

The leading companies in the industry have surged in developing therapies targeted at ferroptosis, including PTC Therapeutics, BeBetter Med, and Sumitomo Pharma. These firms are developing inducers and inhibitors of ferroptosis for use in oncology, among other indications, and neurodegenerative diseases. For instance, a company named PTC Therapeutics is currently focused on vatiquinone, an experimental medication that targets oxidative stress pathways and has shown positive results from clinical trials for cancers and Friedreich's ataxia.

The report sheds light into the R&D strategies and pipelines of these companies, hence allowing stakeholders to have a clear view of where the field is heading. Based on their progress in late-phase trials, there is a high possibility that ferroptosis based therapies are close to commercialization. Additionally, emerging biotech firms and academic collaborations contribute to innovative approaches such as nanocarrier systems and dual-action molecules that may further enhance the efficacy and specificity of ferroptosis therapies.

Report Indicating Future Direction Of Ferroptosis-targeted Therapies

The report predicts that therapies targeting ferroptosis will continue to rapidly evolve, particularly in personalized medicine, and that deeper research into biomarkers will predict patient response with much more personalized, effective treatments that have fewer side effects. It also presents the trend of an increasing number of studies combining ferroptosis inducers with immunotherapy, radiation, and targeted therapies to enhance cancer treatment efficacy. Moreover, advancements in drug delivery systems, such as nanoparticles, are foreseen to enhance targeting and the bioavailability of these therapies.

With continuous clinical trials and increasing investment, the future of treatments based on ferroptosis looks bright; such treatments may even revolutionize the treatment of cancer and other diseases associated with cell death.

1. Research Methodology

2. Harnessing Ferroptosis In Therapeutic Development

2.1 Outline Of Ferroptosis Targeting Therapy
2.2 Chronological Development Of Ferroptosis In Therapeutic Applications

3. Therapeutic Need For Ferroptosis Modulation In Clinical Practice

4. Emerging Diagnostic & Prognostic Potential Of Ferroptosis

5. Strategies For Targeting & Inducing Ferroptosis

5.1 Small Molecules
5.2 Drug Repurposing
5.3 Photodynamic Therapy
5.4 Extracellular Vesicles
5.5 Cell Therapies
5.6 Nanoparticles

6. Ferroptosis Targeting Therapy By Indications: Clinical Trends & Innovations

6.1 Cancer
6.2 Autoimmune & Inflammatory Diseases
6.3 Microbial Infections
6.4 Neurological & Psychiatric Disorders
6.5 Cardiovascular Diseases

7. Global Ferroptosis Targeting Therapy Clinical Trials Overview

7.1 By Phase
7.2 By Country
7.3 By Company
7.4 By Indication
7.5 By Priority Status

8. Global Ferroptosis Targeting Therapy Clinical Trials Insight By Company, Country, Indication & Phase

8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III
8.7 Preregistration
8.8 Registration

9. Global Ferroptosis Targeted Therapy Market - Trends & Developments

9.1 Current Market Overview
9.2 Future Market Forecast

10. Ifupinostat - 1st Approved Ferroptosis Targeting Therapy

11. Ferroptosis Targeting Therapy Market Trends By Region

11.1 US
11.2 China
11.3 Europe
11.4 South Korea

12. Ferroptosis Candidates Granted Regulatory Designations

13. Rational Combination Strategies For Ferroptosis Based Therapies

13.1 Combinations With Conventional Therapies
13.2 Combinations With Immunotherapy
13.3 Combinations With Photodynamic Therapies & Magnetic Fields
13.4 Combinations With Nanotechnology

14. Technological Platforms & Approaches For Ferroptosis Therapeutic Development

14.1 Ferroptosis & Inflammation Platform - PTC Therapeutics
14.2 MIT Platform - MitoImmune
14.3 Non-Viral Gene Therapy Approach - PulseSight

15. Global Ferroptosis Targeting Therapy Market Dynamics

15.1 Market Drivers
15.2 Market Challenges

16. Competitive Landscape

16.1 FELIQS
16.2 FerroptoCure
16.3 MitoImmune Therapeutics
16.4 Prothegen
16.5 PTC Therapeutics
16.6 PulseSight Therapeutics
16.7 Rubedo Life Sciences
16.8 Sumitomo
16.9 Tharimmune
16.10 Vandria

简介目录图表

List of Figures

Figure 2-1: Indications Linked To Ferroptosis
Figure 2-2: Timeline Of Key Discoveries In Regulated Cell Death
Figure 3 1: Clinical Necessity For Ferroptosis Targeting Therapies
Figure 4-1: Ferroptosis As Diagnostic & Prognostic Marker
Figure 5-1: Therapeutic Modalities For Ferroptosis
Figure 6-1: Plant Products Used To Induce Ferroptosis in Cancer Treatment
Figure 6-2: CNSI-Fe(II) Phase I (NCT06048367) Study - Initiation & Completion Year
Figure 6-3: N6F11 - Mode Of Action
Figure 6-4: Capella Phase II (NCT05493800) Study - Initiation & Completion Year
Figure 6-5: PTC743-NEU-003e-FA Phase III (NCT05515536) Study - Initiation & Completion Year
Figure 7-1: Global - Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2026
Figure 7-2: Global - Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2026
Figure 7-3: Global - Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2026
Figure 7-4: Global - Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2026
Figure 7-5: Global - Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2026
Figure 9-1: Ferroptosis-Targeting Therapy Market - Future Opportunities
Figure 14-1: PulseSight - Technology
Figure 15-1: Global Ferroptosis Targeting Therapy Market - Drivers
Figure 15-2: Global Ferroptosis Targeting Therapy Market - Challenges

List of Tables

Table 4-1: Ferroptosis-Related Biomarkers: Diagnostic & Prognostic Roles Across Diseases
Table 5-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis
Table 6-1: Cancer - Reversing Therapy Resistance By Ferroptosis Inducing Compounds
Table 6-2: Autoimmune & Inflammatory Disease - Role Of Ferroptosis
Table 6-3: Autoimmune & Inflammatory Disease - Anti-Ferroptosis Therapeutic Options
Table 6-4: Ferroptosis Effector & Its Mechanism In Nervous System Disorders
Table 6-5: Role Of Ferroptosis In Cardiovascular Diseases
Table 12-1: Ferroptosis Targeting Therapies Granted Regulatory Designations

02-2729-4219

+886-2-2729-4219

License/价格

全球铁凋亡标靶治疗市场：市场机会、治疗方法、技术开发平台和临床试验展望（2026年）

Global Ferroptosis Targeting Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026

目录

第1章研究方法

第2章利用铁凋亡进行治疗开发

第3章临床环境中调控铁凋亡的必要性

第4章铁凋亡的新型诊断与预后潜力

第5章标靶与诱导铁凋亡的策略

第6章依适应症的铁凋亡标靶治疗：临床趋势与创新

第7章铁凋亡标靶治疗临床试验的全球概览

第8章铁凋亡标靶治疗临床试验的全球洞察（依公司、国家、适应症和阶段）

第9章全球铁凋亡标靶治疗市场 - 趋势与发展

第10章伊福司他 - 首个获准的铁凋亡标靶治疗药物

第11章铁凋亡标靶治疗市场趋势（依地区划分）

第12章铁凋亡候选药物的监管认定物质

第13章基于铁凋亡疗法的合理联合策略

第14章铁凋亡疗法开发的技术平台与方法

第15章全球铁凋亡标靶治疗市场动态

第16章竞争格局